An interventional study of CGuard Prime 80cm stent system in Carotid Artery Diseases, sponsored by InspireMD. Recruiting at 8 sites in United States. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2025-05-31.
Sponsored by InspireMD · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Carotid Artery Diseases with a site in United States — 15 open to participants now, 18 under way, none of them phase 3. Carotid Artery Diseases · United States.
Among the 77 studies in Carotid Artery Diseases with a site in United States, this one is the 31st largest by planned enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2024, is one of 23 with no phase, reaches primary completion later than 6 of the 17 other live ones, and was the 69th registered.
260 studies on the registry are indexed under Carotid Artery Diseases; 60 are open to participants now.
Browse Carotid Artery Diseases studies →15 of the 77 studies in Carotid Artery Diseases with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Boston Scientific Corporation · Sites in United States
Ages 18+
Shockwave Medical, Inc. · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+ · Women only
Intervascular · Sites in United States, Belgium, France and 1 more country
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 48 Carotid Artery Diseases studies recruiting now, 33 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
First in 1990; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 144 across 120 interventional studies indexed under Carotid Artery Diseases.
Median enrollment 210 across the 43 interventional studies, 211 across the 34 observational. Of the 51 that completed or were terminated, 22 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 77 have an industry lead sponsor. The 10 most frequent:
InspireMD is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
InspireMD has 2 studies filed under Carotid Artery Diseases — fewer than ten, so there is no comparison to draw.
7 of the studies in Carotid Artery Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02240862University of Maryland, BaltimoreThe CREST-2 Registry | 2026-12-31 |
| NCT02850588Society for Vascular Surgery Patient Safety OrganizationSVS VQI TransCarotid Revascularization Surveillance Project | 2026-12-31 |
| NCT07334834Colorado Prevention CenterImplementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease | 2027-05 |
| NCT07916883Washington University School of MedicinePET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Multisite) | 2027-05-31 |
| NCT05838547Washington University School of MedicineCANF-Comb-II PET-MR in Atherosclerosis Multisite | 2027-05-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 77 studies in Carotid Artery Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate acute device and technical success of the CGuard Prime™ Carotid Stent System (80cm) when used in conjunction with the Enroute NPS during Transcarotid Artery Revascularization procedures in the treatment of carotid artery stenosis in spatients at high risk for adverse events from carotid endarterectomy.
This study is a prospective, multi-center, single arm pivotal study. The study shall not be blinded prior to, during or following the procedure. Patients undergoing transcarotid artery revascularization will be screened against the study inclusion/exclusion criteria. If the patient meets study eligibility requirements, they shall be invited to participate, provide informed consent and shall subsequently be assigned a study ID number.
Enrollment will be a minimum of 50 evaluable pivotal patients. A maximum of 20% of patients will be enrolled at any single site. The total enrollment accounts for an estimate that up to 2 patients will exit the study prior to the 30-day primary endpoint assessment.
An additional roll-in cohort of up to 2 patients per primary physician operator at each study site may also be accrued (maximum of 24 roll-in patients total, assuming one primary physician operator per site).
This study does not duplicate any current knowledge existing today on use of the CGuard Prime™ 80 used in conjunction with the ENROUTE NPS in the United States.
INCLUSION CRITERIA: Candidates for participation in the study must meet all of the following general inclusion criteria.
Comorbid conditions:
Anatomic conditions:
EXCLUSION CRITERIA: Patients are not eligible for the study if they have any of the following exclusion criteria.
Patient has an alternative source of cerebral embolus, including but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: CGuard Prime 80cm stent system
This study is single arm looking at the technical success of the CGuard Prime 80cm stent system when used in conjunction with the FDA-cleared ENROUTE NPS during a TCAR procedure.
Acute device success
Successful insertion of the delivery system, successful deployment of the CGuard Prime™ 80 stent, and successful retraction of the delivery system when used in conjunction with the FDA-cleared ENROUTE NPS during a TCAR procedure.
Time frame: From enrollment to end of follow-up at 1 year
Technical success
Technical Success Rate is defined as the number of patients with at least one CGuard Prime™ 80 device successfully delivered and deployed with final residual diameter stenosis \< 30% following final post-balloon dilatation (if performed) divided by the total number of patients where CGuard Prime™ 80 device deployment was attempted when used in conjunction with the FDA-cleared ENROUTE NPS during a TCAR procedure.
Time frame: From enrollment to end of follow-up at 1 year
Procedural success
Acute device success for CGuard PrimeTM 80 Delivery System and Stent without experiencing death, stroke or MI through 30-day post-procedure when used in conjunction with the FDA-cleared ENROUTE NPS during a TCAR procedure.
Time frame: From enrollment to 30-day follow-up
Treatment success
Treatment Success Rate is defined as the number of patients who meet CGuard Prime™ 80 Technical Success Rate without experiencing death, stroke or MI through 30-day post-procedure, divided by the total number of patients where CGuard Prime™ 80 device deployment was attempted when used in conjunction with the FDA-cleared ENROUTE NPS during a TCAR procedure.
Time frame: From enrollment to 30-day follow-up
Occurence of Hierarchical Death, Stroke or Myocardial Infarction (DSMI) within 30 days of the procedure
Time frame: From enrollment to 30-day follow-up
Hierarchical Death or Stroke rate within 30 days of the procedure
Time frame: From enrollment to 30-day follow-up
Rate of death within 30 days of the procedure
Time frame: From enrollment to 30-day follow-up
Rate of all strokes within 30 days of the procedure
Time frame: From enrollment to 30-day follow-up
Rate of major stroke within 30 days of the procedure
Time frame: From enrollment to 30-day follow-up
Rate of minor stroke within 30 days of the procedure
Time frame: From enrollment to 30-day follow-up
Rate of Myocardial Infarction (MI) within 30 days of the procedure
Time frame: From enrollment to 30-day follow-up
Rate of stent thrombosis or occlusion within 30 days of the index procedure
Time frame: From enrollment to 30-day follow-up
Rate of stent thrombosis or occlusion through 1-year of the index procedure
Time frame: From enrollment to end of follow-up at 1 year
All device-related serious adverse events within 30 days of the procedure
Time frame: From enrollment to 30-day follow-up
All device-related serious adverse events through 1-year of the procedure
Time frame: From enrollment to end of follow-up at 1 year
Rate of ipsilateral strokes between 31- and 365-day post index procedure
Time frame: From time of 30-day follow-up to end of follow-up at 1 year
Started Nov 2024 (actual). Primary completion is estimated for Nov 2026, 24 months after the start.
Of 42 interventional studies with no phase under Carotid Artery Diseases, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 59. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
InspireMD